Pfizer Says FDA Approved ABRYSVO (Respiratory Syncytial Virus Vaccine) For The Prevention Of Lower Respiratory Tract Disease Caused By RSV In Individuals 60 Years And Older
Portfolio Pulse from Benzinga Newsdesk
Pfizer announced that the FDA has approved ABRYSVO, a vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals aged 60 and older. The approval is based on data from the pivotal Phase 3 clinical trial RENOIR.
May 31, 2023 | 9:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's ABRYSVO vaccine has received FDA approval for preventing lower respiratory tract disease caused by RSV in individuals aged 60 and older.
The FDA approval of ABRYSVO is a positive development for Pfizer, as it expands the company's product portfolio and addresses a significant unmet medical need in the prevention of lower respiratory tract disease caused by RSV in older individuals. This is likely to have a positive impact on Pfizer's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100